National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 2 of 2 Research Studies DisplayedScott FI, Mamtani R, Brensinger CM
Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer.
The study objective was to determine the relative hazard of a second nonmelanoma skin cancer (NMSC) in patients with rheumatoid arthritis and inflammatory bowel disease who use methotrexate, anti-tumor necrosis factor (anti-TNF) therapy, or thiopurines after an initial NMSC. It concluded that methotrexate use is associated with an increased risk of a second NMSC.
AHRQ-funded; HS018517.
Citation: Scott FI, Mamtani R, Brensinger CM .
Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer.
JAMA Dermatol 2016 Feb;152(2):164-72. doi: 10.1001/jamadermatol.2015.3029.
.
.
Keywords: Cancer, Arthritis, Risk, Comparative Effectiveness, Treatments
Ko EM, Sturmer T, Hong JL
Metformin and the risk of endometrial cancer: a population-based cohort study.
The researchers sought to estimate the risk of incident endometrial cancer in women who were new users of metformin compared to new users of sulfonylureas. They did not find a difference in cancer incidence in new initiators of metformin compared with sulfonylureas in the population under study.
AHRQ-funded; HS017950.
Citation: Ko EM, Sturmer T, Hong JL .
Metformin and the risk of endometrial cancer: a population-based cohort study.
Gynecol Oncol 2015 Feb;136(2):341-7. doi: 10.1016/j.ygyno.2014.12.001..
Keywords: Comparative Effectiveness, Cancer, Medication, Risk